Back to search results

Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

This study is looking at how well a continuous glucose monitor (CGM) called Dexcom G6 PRO works for people with diabetes who are receiving care through the Mayo Clinic Advanced Care at Home (ACH) program. The Dexcom G6 PRO sends your blood sugar readings to a smartphone, which then shares the data with the ACH team for monitoring. Researchers want to see if using this CGM, along with diabetes education, improves blood sugar control compared to standard blood sugar checks (glucometer) and education. To join, you must be at least 18 years old, have type 1 or type 2 diabetes, be taking insulin, and be admitted to the ACH program for at least 72 hours. The study will measure how much time your blood sugar stays in a healthy range and your average daily blood sugar over 10 days. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 100 participants. It compares the use of a continuous glucose monitor to standard blood sugar monitoring.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measures of blood sugar control will be taken at 10 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05880810

Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

Recruiting
NAAges 18+InterventionalTreatment
Mayo Clinic
~100 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:Continuous Glucose Monitor Dexcom G6 PRO

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time in Range
Measured over 10 days
+1 more outcome measured

Conditions

Diabetes Mellitus

Explore related trials

Diabetes Mellitus

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Adrian Dumitrascu, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Adrian Dumitrascu, MD
[email protected]
904-953-2000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients who are admitted to Advanced Care at Home (ACH) Program and supposed to remain in ACH for at least 72 hours.
Patients with previous diagnosis of DM type 1 or type 2.
Patients taking subcutaneous (SQ) insulin either via multidose injections or SQ insulin pump.
Capable of giving signed informed consent

Exclusion

Actively treated for diabetes ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS).
Participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours.
Participants with altered mental status.
Participants diagnosed with dementia.
Patients with suicidal ideations or experiencing suicidal behavior.
Patients with liver cirrhosis.
Patients with End Stage Renal Disease on dialysis bot hemodialysis or peritoneal dialysis.
Participants with allergy to medical grade adhesive or medical tape.
Participants taking hydroxyurea.
Participants who are pregnant, wanting to become pregnant, or nursing during study period.
Patients with a planned MRI within the following 10 days after admission to ACH.
Participants currently using continuous glucose monitor (CGM) to dose insulin or check glucose level.
Participants with diabetes mellitus (DM) treated with diet alone.
Participants with DM treated with oral hypoglycemic medications.
Participants with DM treated with one SQ insulin injection daily.
Participants enrolled in other studies addressing CGM use.
Participants physically or emotionally incapable of handling a cell phone with a smart display.
Participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm.
Patients lacking WIFI or Cellular coverage needed to connect the monitoring cell phone to Internet network.

What this trial measures

  • Time in Range10 days

    Percentage of time with continuous glucose monitor values within 70-180 mg/dl

  • Mean daily glucose10 days

    Mean daily glucose level (mg/dl)